Donepezil
- Generic Name
- Donepezil
- Brand Names
- Adlarity, Aricept, Namzaric
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29NO3
- CAS Number
- 120014-06-4
- Unique Ingredient Identifier
- 8SSC91326P
- Background
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other ty...
- Indication
Donepezil, administered orally or via transdermal delivery system, is indicated for the treatment of dementia of the Alzheimer's type. It is also available as an extended-release capsule in combination with memantine for the treatment of moderate-to-severe dementia of the Alzheimer's type in patients previously stabilized on 10mg of donepezil hydrochloride o...
- Associated Conditions
- Alzheimer's Disease (AD), Dementia With Lewy Body Disease, Dementia due to Parkinson's disease, Dementia of the Alzheimer's Type, Vascular Dementia (VaD), Moderate Alzheimer's Type Dementia, Severe Alzheimer's Type Dementia
- Associated Therapies
- -
A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients
- Conditions
- Interventions
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- University of Chicago
- Registration Number
- NCT02857244
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 241
- Registration Number
- NCT02787746
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 179
- Registration Number
- NCT02769065
DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2020-02-12
- Target Recruit Count
- 92
- Registration Number
- NCT02711683
- Locations
- 🇨🇳
First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease
- Conditions
- Interventions
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 302
- Registration Number
- NCT02660983
Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects
- First Posted Date
- 2015-12-21
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT02635750
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
- Conditions
- Interventions
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 564
- Registration Number
- NCT02580305
- Locations
- 🇺🇸
Senior Clinical Trials, Inc., Laguna Hills, California, United States
🇺🇸Emerald Coast Center for Neurological Disorders, Pensacola, Florida, United States
🇺🇸Neurological Associates of Albany, PC, Albany, New York, United States
A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2019-03-05
- Target Recruit Count
- 28
- Registration Number
- NCT02549196
- Locations
- 🇺🇸
PMG Research, Winston-Salem, North Carolina, United States
🇺🇸Quantum Laboratories, Deerfield Beach, Florida, United States
🇺🇸Miami Jewish Health Systems, Miami, Florida, United States
Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 176
- Registration Number
- NCT02550665
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI)
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 80
- Registration Number
- NCT02450786
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.